UNITI-1

November 18, 2016November 18, 2016

Stelara, Treatment for Moderate-to-Severe Crohn’s Disease, Approved for Use in EU

News

The European Commission (EC) has approved Stelara (ustekinumab) for the treatment of adults with moderate-to-severe Crohn’s disease who had no improvements with other therapies, the drug developer’s, Janssen, announced. Stelara is ... Read more

September 23, 2016

European Agency Recommends Approval of Stelara to Treat Crohn’s Disease

News

The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency (EMA), has issued a positive opinion on Janssen’s Stelara (ustekinumab) for the treatment of patients with moderate-to-severe active ... Read more

March 28, 2016March 28, 2016

Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results

News

Janssen Pharmaceuticals’ drug candidate Stelara (ustekinumab) demonstrated positive therapeutic effects in a recent Phase 3 clinical trial, inducing clinical response and remission in adult patients with moderate to severe Crohn’s ... Read more